BTAI stock · FITB stock

BTAI vs FITB · rev $388.0K vs P/E 17, rev $3.37B

BioXcel Therapeutics Inc (BTAI) versus Fifth Third Bancorp (FITB) — a side-by-side from cached financials, not a winner call.

BioXcel Therapeutics Inc (BTAI) is a drug manufacturers - specialty & generic company listed on US.

Fifth Third Bancorp (FITB) is a banks - regional company listed on US.

Latest reported BTAI revenue for 2026-06-30 was $388.0K. Net income was -$27.4M. Revenue was up 88.3% from 2026-03-31 to 2026-06-30. BTAI currently screens at market cap $36.1M.

Latest reported FITB revenue for 2026-06-30 was $3.37B. Net income was $801.0M. Revenue was up 13.5% from 2026-03-31 to 2026-06-30. FITB currently screens at market cap $45.25B and trailing P/E 16.8.

BTAI currently screens at market cap $36.1M. FITB currently screens at market cap $45.25B and trailing P/E 16.8.

Not investment advice. Open the BTAI and FITB stock pages for the full models.

Not investment advice.

Popular Stock Comparisons